Photo from Novartis' Indianapolis plant (Credit: Novartis)
Lutetium, actinium or lead: Can isotope type offer an edge in radiotherapy?
Once considered a niche cancer therapy, radioligands are in the midst of a renaissance.
“If you think about where ADCs were four or five years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
